StreetInsider.com News Articles

Form 4 CRISPR Therapeutics AG For: Mar 10 Filed by: KASINGER JAMES R.

Thu, 12 Mar 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260312/26154724.html

Form 4 CRISPR Therapeutics AG For: Mar 10 Filed by: KASINGER JAMES R.

Thu, 12 Mar 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260312/26154724.html

Form 4 CRISPR Therapeutics AG For: Mar 10 Filed by: Kulkarni Samarth

Thu, 12 Mar 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260312/26154726.html

Form 4 CRISPR Therapeutics AG For: Mar 10 Filed by: Kulkarni Samarth

Thu, 12 Mar 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260312/26154726.html

Form 8-K CRISPR Therapeutics AG For: Mar 10

Wed, 11 Mar 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260311/26142560.html

Form 8-K CRISPR Therapeutics AG For: Mar 10

Wed, 11 Mar 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260311/26142560.html

CRISPR Therapeutics prices $550 million convertible notes offering

Wed, 11 Mar 2026 07:00:41 -0400

CRISPR Therapeutics AG (NASDAQ: CRSP) announced the pricing of $550 million aggregate principal amount of convertible senior notes due 2031 in a private offering to qualified institutional buyers. The offering was increased from the previously announced $350 million.

The notes carry an effective coupon of 1.125% for investors, though the company will pay 1.7308% to offset anticipated Swiss withholding taxes. Interest payments will occur semiannually on March 1 and September 1, beginning September 1, 2026. The notes mature on March 1, 2031.

Initial purchasers received an option to buy an additional $50 million of notes within 13 days of issuance. The sale

CRISPR Therapeutics prices $550 million convertible notes offering

Wed, 11 Mar 2026 07:00:41 -0400

Initial purchasers received an option to buy an additional $50 million of notes within 13 days of issuance. The sale

CRISPR Therapeutics prices $550 million convertible notes offering

Wed, 11 Mar 2026 07:00:41 -0400

Initial purchasers received an option to buy an additional $50 million of notes within 13 days of issuance. The sale

CRISPR Therapeutics prices $550 million convertible notes offering

Wed, 11 Mar 2026 07:00:41 -0400

Initial purchasers received an option to buy an additional $50 million of notes within 13 days of issuance. The sale

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Wed, 11 Mar 2026 07:00:00 -0400

ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued,

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Wed, 11 Mar 2026 07:00:00 -0400

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Wed, 11 Mar 2026 07:00:00 -0400

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Wed, 11 Mar 2026 07:00:00 -0400

CRISPR Therapeutics announces $350 million convertible notes offering

Tue, 10 Mar 2026 07:01:35 -0400

CRISPR Therapeutics AG (NASDAQ: CRSP) announced plans to offer $350 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers.

The biotechnology company said it will grant initial purchasers an option to buy up to an additional $52.5 million of the notes within 13 days of issuance. The notes will be senior, unsecured obligations that accrue interest payable twice yearly on March 1 and September 1, beginning September 1, 2026.

The notes mature on March 1, 2031, unless converted, redeemed or repurchased earlier. Upon conversion, the company will deliver common shares with a nominal value of CHF

CRISPR Therapeutics announces $350 million convertible notes offering

Tue, 10 Mar 2026 07:01:35 -0400

CRISPR Therapeutics AG (NASDAQ: CRSP) announced plans to offer $350 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers.

The notes mature on March 1, 2031, unless converted, redeemed or repurchased earlier. Upon conversion, the company will deliver common shares with a nominal value of CHF

CRISPR Therapeutics announces $350 million convertible notes offering

Tue, 10 Mar 2026 07:01:35 -0400

CRISPR Therapeutics AG (NASDAQ: CRSP) announced plans to offer $350 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers.

The notes mature on March 1, 2031, unless converted, redeemed or repurchased earlier. Upon conversion, the company will deliver common shares with a nominal value of CHF

CRISPR Therapeutics announces $350 million convertible notes offering

Tue, 10 Mar 2026 07:01:35 -0400

CRISPR Therapeutics AG (NASDAQ: CRSP) announced plans to offer $350 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers.

The notes mature on March 1, 2031, unless converted, redeemed or repurchased earlier. Upon conversion, the company will deliver common shares with a nominal value of CHF

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Tue, 10 Mar 2026 07:00:00 -0400

ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Tue, 10 Mar 2026 07:00:00 -0400

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Tue, 10 Mar 2026 07:00:00 -0400

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Tue, 10 Mar 2026 07:00:00 -0400

Form 4 CRISPR Therapeutics AG For: Feb 18 Filed by: Kulkarni Samarth

Fri, 20 Feb 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260220/26037408.html

Form 4 CRISPR Therapeutics AG For: Feb 18 Filed by: Kulkarni Samarth

Fri, 20 Feb 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260220/26037408.html

Form 4 CRISPR Therapeutics AG For: Feb 18 Filed by: KASINGER JAMES R.

Fri, 20 Feb 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260220/26037403.html